Table 1.
Characteristics of patients included in the study
| Age (years), mean (SD) | 61.4 (10.8) |
| Male/Women (n) | 19/8 |
| BMI (kg/m²), mean (SD) | 24.6 (3.2) |
| Body weight (kg), mean (SD) | 64.9 (8.9) |
| HbA1c (%), mean (SD) | 7.4 (1.0) |
| Fasting plasma glucose levels (mg/dL), mean (SD) | 145.8 (35.9) |
| Duration of diabetes (years), mean (SD) | 8.8 (7.6) |
| Alcohol consumption, % | 36.0 |
| Smoking, % | 44.0 |
| eGFR (mL/min/1.73 m2), mean (SD) | 82.7 (21.1) |
| ACR (mg/gCr), mean (SD) | 34.1 (54.6) |
| Systolic blood pressure (mmHg), mean (SD) | 129.8 (8.0) |
| Diastolic blood pressure (mmHg), mean (SD) | 79.7 (7.3) |
| LDLC(mg/dL), mean (SD) | 120.5 (31.4) |
| HDLC (mg/dL) mean (SD) | 53.2 (14.0) |
| TG (mg/dL), mean (SD) | 134.3 (49.4) |
| Retinopathy, % | 14.8 |
| Neuropathy, % | 31.8 |
| Nephropathy, % | 29.6 |
| Cardiovascular diseases, % | 3.7 |
| Oral hypoglycemic agent | N (%)* |
|---|---|
| α-glucosidase inhibitors | 0 |
| Sulfonylureas | 8 (29.6) |
| Biguanides | 16 (59.2) |
| Glinide | 0 |
| SGLT2 inhibitors | 0 |
| Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers | 9 (33.3) |
| Statin | 10 (37.0) |
SD standard deviation, BMI body mass index, eGFR estimated glomerular filtration rate, ACR albumin creatinine ratio, HbA1c hemoglobin A1c, LDLC low-density lipoprotein cholesterol, HDLC high-density lipoprotein cholesterol, TG triglyceride, cardiovascular diseases comprise angina pectoris, myocardial infarction, stroke, and arteriosclerosis obliterans; SGLT2 sodium glucose cotransporter 2
* There is a case of duplicates